

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e perfluorocarbon

E1	4	PERFLUOROCAPRYLATE/BI
E2	4	PERFLUOROCAPRYLIC/BI
E3	2 -->	PERFLUOROCARBON/BI
E4	1	PERFLUOROCARBONS/BI
E5	2	PERFLUOROCOAT/BI
E6	11	PERFLUOROCT/BI
E7	2	PERFLUOROCTAN/BI
E8	1	PERFLUOROCTANAMID/BI
E9	1	PERFLUOROCTANAMIDOX/BI
E10	1	PERFLUOROCTANAMIDOXIME/BI
E11	1	PERFLUOROCTANE/BI
E12	1	PERFLUOROCTANESULFON/BI

=> s e1-e12

	4	PERFLUOROCAPRYLATE/BI
	4	PERFLUOROCAPRYLIC/BI
	2	PERFLUOROCARBON/BI
	1	PERFLUOROCARBONS/BI
	2	PERFLUOROCOAT/BI
	11	PERFLUOROCT/BI
	2	PERFLUOROCTAN/BI
	1	PERFLUOROCTANAMID/BI
	1	PERFLUOROCTANAMIDOX/BI
	1	PERFLUOROCTANAMIDOXIME/BI
	1	PERFLUOROCTANE/BI
	1	PERFLUOROCTANESULFON/BI
L1	26	(PERFLUOROCAPRYLATE/BI OR PERFLUOROCAPRYLIC/BI OR PERFLUOROCARBO N/BI OR PERFLUOROCARBONS/BI OR PERFLUOROCOAT/BI OR PERFLUOROCT/B I OR PERFLUOROCTAN/BI OR PERFLUOROCTANAMID/BI OR PERFLUOROCTANAM IDOX/BI OR PERFLUOROCTANAMIDOXIME/BI OR PERFLUOROCTANE/BI OR PERFLUOROCTANESULFON/BI)

=> fil caplus biosis medline uspatful embase

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		62.26	62.47

FILE 'CAPLUS' ENTERED AT 13:14:28 ON 12 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:14:28 ON 12 FEB 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 13:14:28 ON 12 FEB 2008

FILE 'USPATFULL' ENTERED AT 13:14:28 ON 12 FEB 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:14:28 ON 12 FEB 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s l1 or (perfluor?)  
L2 143119 L1 OR (PERFLUOR?)

<-----User Break----->

<-----User Break----->

=> s l2 and (emulsion?)  
L3 25249 L2 AND (EMULSION?)

=> s l3 and (nerv? or endocrin?)  
L4 3019 L3 AND (NERV? OR ENDOCRIN?)

=> s l4 and (capillar?)  
L5 820 L4 AND (CAPILLAR?)

=> s l5 and (skin(p)capillar?)  
L6 70 L5 AND (SKIN(P) CAPILLAR?)

=> dup rem l6  
PROCESSING COMPLETED FOR L6  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 and (py<=2005)  
3 FILES SEARCHED...  
L8 50 L7 AND (PY<=2005)

=> d ibib ab 1-  
YOU HAVE REQUESTED DATA FROM 50 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:331347 USPATFULL <<LOGINID::20080212>>

TITLE: Controlling angiogenesis with anabaseine analogs  
INVENTOR(S): Kem, William R., Gainesville, FL, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005288333 A1 20051229 <--  
APPLICATION INFO.: US 2005-147996 A1 20050608 (11)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-577990P 20040608 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST  
PALM BEACH, FL,  
33402-3188, US  
NUMBER OF CLAIMS: 63  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 3279  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds controlling angiogenesis and vasculogenesis. In particular,  
induction of angiogenesis to promote growth of new vasculature by the  
use of anabaseine agonists and to the reduction of pathological  
angiogenesis by the use of anabaseine antagonists.

L8 ANSWER 2 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:274051 USPATFULL <<LOGINID::20080212>>

TITLE: Compositions and methods for topical delivery of  
oligonucleotides  
INVENTOR(S): Dokka, Sujatha, San Marcos, CA, UNITED STATES  
Cooper, Scott, Petaluma, CA, UNITED STATES  
Kelly, Susan, San Diego, CA, UNITED STATES  
Hardee, Greg, San Diego, CA, UNITED STATES  
Karras, James G., San Marcos, CA, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005238606 A1 20051027 <--  
APPLICATION INFO.: US 2005-112451 A1 20050421 (11)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-565244P 20040423 (60)  
US 2004-592577P 20040729 (60)  
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: COZEN O'CONNOR, P.C., 1900 MARKET STREET,  
PHILADELPHIA,

PA, 19103-3508, US

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 1792

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.

L8 ANSWER 3 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:240095 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005208095 A1 20050922 <--

APPLICATION INFO.: US 2004-996354 A1 20041122 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-986231, filed  
on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 101  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 34089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 4 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:226572 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005196421 A1 20050908 <--

APPLICATION INFO.: US 2004-1417 A1 20041201 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
NUMBER OF CLAIMS: 100  
EXEMPLARY CLAIM: 1-7300  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 34222  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 5 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:220596 USPATFULL <<LOGINID::20080212>>  
TITLE: Medical implants and anti-scarring agents  
INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.  
corporation)

NUMBER KIND DATE  
-----  
PATENT INFORMATION: US 2005191331 A1 20050901 <--  
APPLICATION INFO.: US 2004-1419 A1 20041130 (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER DATE  
-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178  
EXEMPLARY CLAIM: 1-2104  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 56419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 6 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:215570 USPATFULL <<LOGINID::20080212>>

TITLE: Cell proliferation inhibitors

INVENTOR(S): Li, Qun, Libertyville, IL, UNITED STATES  
Sham, Hing, Mundelein, IL, UNITED STATES  
Woods, Keith W., Libertyville, IL, UNITED STATES  
Steiner, Beth A., Remington, IN, UNITED STATES  
Gwaltney, Stephen L. II, Lindenhurst, IL, UNITED STATES  
Barr, Kenneth J., San Francisco, CA, UNITED STATES  
Imade, Hovis M., Chicago, IL, UNITED STATES  
Rosenberg, Saul, Grayslake, IL, UNITED STATES

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005187246 A1 20050825 <--  
APPLICATION INFO.: US 2005-109017 A1 20050419 (11)  
RELATED APPLN. INFO.: Division of Ser. No. US 2002-301427, filed on 21 Nov  
2002, PENDING Division of Ser. No. US 2000-579705,  
filed on 26 May 2000, GRANTED, Pat. No. US 6521658

NUMBER DATE

-----

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT  
LABORATORIES, 100 ABBOTT  
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008,  
US

NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having formula (I) ##STR1## inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 7 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:215464 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005187140 A1 20050825 <--

APPLICATION INFO.: US 2004-408 A1 20041129 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2004-611077P 20040917 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)



US 2003-523908P 20031120 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
NUMBER OF CLAIMS: 103  
EXEMPLARY CLAIM: 1-5846  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 34103  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 8 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:214572 USPATFULL <<LOGINID::20080212>>  
TITLE: Polymer compositions and methods for their use  
INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.  
corporation)

NUMBER KIND DATE  
-----  
PATENT INFORMATION: US 2005186244 A1 20050825 <--  
APPLICATION INFO.: US 2004-1790 A1 20041202 (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE  
-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 103

EXEMPLARY CLAIM: 1-8540

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 9 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:212068 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A.E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005183731 A1 20050825 <--

APPLICATION INFO.: US 2004-6908 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 52  
EXEMPLARY CLAIM: 1-8061  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 34032

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 10 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:212065 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304  
(non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005183728 A1 20050825 <--

APPLICATION INFO.: US 2004-7836 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178  
EXEMPLARY CLAIM: 1-3411  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 56413

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 11 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:209978 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304  
(non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005182463 A1 20050818 <--

APPLICATION INFO.: US 2004-1788 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 125

EXEMPLARY CLAIM: 1-8059

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 34070

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 12 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:209494 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005181977 A1 20050818 <--

APPLICATION INFO.: US 2004-986231 A1 20041110 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 182  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 56396  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 13 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:208533 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005181011 A1 20050818 <--

APPLICATION INFO.: US 2004-1792 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER      DATE

-----  
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE:      Utility

FILE SEGMENT:      APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS:    177

EXEMPLARY CLAIM:    1-4994

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT:          56421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB    Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8    ANSWER 14 OF 50    USPATFULL on STN

ACCESSION NUMBER:    2005:208530    USPATFULL <<LOGINID::20080212>>

TITLE:                  Medical implants and anti-scarring agents

INVENTOR(S):          Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S):    Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005181008 A1 20050818 <--  
APPLICATION INFO.: US 2004-1786 A1 20041202 (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
Nov 2004, PENDING

NUMBER      DATE

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-4736

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 15 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:205930 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA



Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-  
U.S.  
corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005178396 A1 20050818 <--		
APPLICATION INFO.: US 2004-6905 A1 20041207 (11)		
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING		

NUMBER	DATE
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)	
US 2004-586861P 20040709 (60)	
US 2004-566569P 20040428 (60)	
US 2003-526541P 20031203 (60)	
US 2003-525226P 20031124 (60)	
US 2003-523908P 20031120 (60)	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH	

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
NUMBER OF CLAIMS: 50  
EXEMPLARY CLAIM: 1-8063  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 33965

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

L8 ANSWER 16 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:205929 USPATFULL <<LOGINID::20080212>>  
TITLE: Polymer compositions and methods for their use  
INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-  
U.S.  
corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005178395 A1 20050818 <--		
APPLICATION INFO.: US 2004-6900 A1 20041207 (11)		
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING		

NUMBER	DATE
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)	
US 2004-586861P 20040709 (60)	
US 2004-566569P 20040428 (60)	
US 2003-526541P 20031203 (60)	
US 2003-525226P 20031124 (60)	
US 2003-523908P 20031120 (60)	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION	
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH	

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US  
NUMBER OF CLAIMS: 58  
EXEMPLARY CLAIM: 1-7302  
NUMBER OF DRAWINGS: 32 Drawing Page(s)  
LINE COUNT: 34043

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

L8 ANSWER 17 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:203799 USPATFULL <<LOGINID::20080212>>  
TITLE: Medical implants and anti-scarring agents  
INVENTOR(S): Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
    Maiti, Arpita, Vancouver, CANADA  
    Signore, Pierre E., Vancouver, CANADA  
    Liggins, Richard T., Coquitlam, CANADA  
PATENT ASSIGNEE(S):  Angiotech International AG, Zug, SWITZERLAND, CH  
                         (non-U.S. corporation)

          NUMBER      KIND      DATE

-----  
PATENT INFORMATION:  US 2005177225      A1  20050811      <--  
APPLICATION INFO.:   US 2004-6895      A1  20041207  (11)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10  
                         Nov 2004, PENDING

          NUMBER      DATE

-----  
PRIORITY INFORMATION: US 2004-586861P  20040709 (60)  
                         US 2004-578471P  20040609 (60)  
                         US 2003-526541P  20031203 (60)  
                         US 2003-525226P  20031124 (60)  
                         US 2003-523908P  20031120 (60)  
                         US 2003-524023P  20031120 (60)  
                         US 2003-518785P  20031110 (60)

DOCUMENT TYPE:      Utility  
FILE SEGMENT:       APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

                  AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS:   173  
EXEMPLARY CLAIM:    1-11788  
NUMBER OF DRAWINGS:  28 Drawing Page(s)  
LINE COUNT:         56371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB  Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 18 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202285 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A.E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005175703 A1 20050811 <--

APPLICATION INFO.: US 2004-6888 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22

Nov 2004, PENDING Continuation-in-part of Ser. No. US

2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 55

EXEMPLARY CLAIM: 1-7576

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 33992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and

the prevention of cartilage loss.

L8 ANSWER 19 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202247 USPATFULL <<LOGINID::20080212>>

TITLE: Polymer compositions and methods for their use

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005175665 A1 20050811 <--

APPLICATION INFO.: US 2004-6896 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22  
Nov 2004, PENDING Continuation-in-part of Ser. No. US  
2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 51

EXEMPLARY CLAIM: 1-7822

NUMBER OF DRAWINGS: 32 Drawing Page(s)

LINE COUNT: 33978

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,

treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 20 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:202245 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005175663 A1 20050811 <--

APPLICATION INFO.: US 2004-1791 A1 20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 180

EXEMPLARY CLAIM: 1-3944

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a

second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 21 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:190568 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005165488 A1 20050728 <--

APPLICATION INFO.: US 2004-6912 A1 20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 176

EXEMPLARY CLAIM: 1-3153

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56407

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 22 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:184075 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

Stafford, Jeffrey A., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005159470 A1 20050721 <--

APPLICATION INFO.: US 2004-13056 A1 20041214 (11)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-531567P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,

92121, US

NUMBER OF CLAIMS: 70

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 4483

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Histone deacetylase inhibitors and uses thereof are provided that have the general Z-Q-L-M



wherein Z is a 5-membered aromatic heterocycle as shown herein, each X is independently selected from the group consisting of CR.sub.5 and N; each Y is independently selected from the group consisting of O, S and NR.sub.5; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein; Q is a substituted or unsubstituted aromatic ring; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 1-10 atoms connecting the M substituent to the Q substituent.

L8 ANSWER 23 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:172409 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005149158 A1 20050707 <--

APPLICATION INFO.: US 2004-409 A1 20041129 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178

EXEMPLARY CLAIM: 1-274

NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 24 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:172331 USPATFULL <<LOGINID::20080212>>

TITLE: Medical implants and anti-scarring agents

INVENTOR(S): Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Tolekis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.

corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005149080 A1 20050707 <--

APPLICATION INFO.: US 2004-1418 A1 20041130 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP  
PLLC, 701 FIFTH

AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

NUMBER OF CLAIMS: 178  
EXEMPLARY CLAIM: 1-806  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 56418

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 25 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:164658 USPATFULL <<LOGINID::20080212>>

TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor

INVENTOR(S): Breton, Lionel, Versailles, FRANCE  
Mahe, Yann, Morsang sur Orge, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005142081 A1 20050630 <--  
APPLICATION INFO.: US 2005-65356 A1 20050225 (11)  
RELATED APPLN. INFO.: Division of Ser. No. US 2002-179934, filed on 26 Jun  
2002, GRANTED, Pat. No. US 6884425

NUMBER DATE

-----

PRIORITY INFORMATION: FR 2001-8433 20010626  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER &  
NEUSTADT, P.C., 1940

DUKE STREET, ALEXANDRIA, VA, 22314, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1-16

LINE COUNT: 1196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 26 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:159024 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005137234 A1 20050623 <--

APPLICATION INFO.: US 2004-13234 A1 20041214 (11)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-531371P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,

92121, US

NUMBER OF CLAIMS: 98

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 4764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Histone deacetylase inhibitors and uses thereof are provided that have the general formula: Z-L-M wherein Z, L and M are as defined herein.

L8 ANSWER 27 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:159022 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES  
Stafford, Jeffrey A., San Diego, CA, UNITED STATES  
Vu, Phong H., San Diego, CA, UNITED STATES  
Xiao, Xiao-Yi, San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005137232 A1 20050623 <--  
APPLICATION INFO.: US 2004-803580 A1 20040317 (10)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2003-455437P 20030317 (60)  
US 2003-531203P 20031219 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,  
92121, US  
NUMBER OF CLAIMS: 144  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Page(s)  
LINE COUNT: 4750  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the  
formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of  
complexing with a deacetylase catalytic site and/or a metal ion; L is a  
substituent providing between 0-10 atoms separation between the M  
substituent and the remainder of the compound; and Z and Q are as  
defined herein.

L8 ANSWER 28 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:118290 USPATFULL <<LOGINID::20080212>>  
TITLE: Method and compositions for the treatment and  
prevention of pain and inflammation  
INVENTOR(S): Pulaski, Steven P., Simi Valley, CA, UNITED STATES  
Kundel, Susan, Basel, SWITZERLAND  
PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO, UNITED  
STATES  
(U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2005101563 A1 20050512 <--  
APPLICATION INFO.: US 2004-783160 A1 20040219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-215539, filed  
on 9 Aug 2002, PENDING

NUMBER DATE

-----

PRIORITY INFORMATION: US 2001-312211P 20010814 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HARNESS, DICKEY & PIERCE, P.L.C., 7700  
BONHOMME, SUITE

400, ST LOUIS, MO, 63105, US

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

LINE COUNT: 4596

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preventing or treating pain or inflammation in a subject is  
provided by administering to the subject a Cox-2 inhibitor and a  
polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of  
a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically  
acceptable salt or prodrug thereof together constitute a pain or  
inflammation suppressing treatment or prevention effective amount.  
Glucosamine and/or chondroitin can optionally be present. Therapeutic  
compositions that contain the combination of Cox-2 inhibitor and  
polyunsaturated fatty acid and, optionally, the glucosamine and/or  
chondroitin, are disclosed, as are pharmaceutical compositions.

L8 ANSWER 29 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2005:112275 USPATFULL <<LOGINID::20080212>>

TITLE: Inhibitors of semicarbazide-sensitive amine oxidase  
(SSAO) and VAP-1 mediated adhesion useful for treatment  
of diseases

INVENTOR(S): Salter-Cid, Luisa Maria, San Diego, CA, UNITED STATES  
Wang, Eric Yanjun, San Diego, CA, UNITED STATES  
Cockerill, Keith, San Diego, CA, UNITED STATES  
Linnik, Matthew D., Solana Beach, CA, UNITED STATES  
Victoria, Edward J., San Diego, CA, UNITED STATES

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2005096360 A1 20050505 <--

APPLICATION INFO.: US 2004-913253 A1 20040806 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-493835P 20030808 (60)

US 2003-502401P 20030912 (60)

US 2004-568999P 20040506 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL  
RD, PALO ALTO,  
CA, 94304-1018, US

NUMBER OF CLAIMS: 65  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 3282  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods of using compositions for treatment of  
inflammatory diseases and immune disorders are provided. Allylhydrazine  
compounds, hydroxylamine (aminooxy) compounds, and other compounds are  
disclosed which are inhibitors of semicarbazide-sensitive amine oxidase  
(SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have  
therapeutic utility in suppressing inflammation and inflammatory  
responses, and in treatment of several disorders, including multiple  
sclerosis.

L8 ANSWER 30 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2005:68473 USPATFULL <<LOGINID::20080212>>  
TITLE: Preventing and/or combating collagen fiber degradation  
induced under conditions of natural exposure to  
sunlight  
INVENTOR(S): Fagot, Dominique, Paris, FRANCE  
Bernerd, Françoise, Paris, FRANCE  
PATENT ASSIGNEE(S): L'OREAL, PARIS, FRANCE (non-U.S. corporation)

NUMBER	KIND	DATE
-----		
PATENT INFORMATION:	US 2005058611	A1 20050317 <--
APPLICATION INFO.:	US 2004-922929	A1 20040823 (10)

NUMBER	DATE
-----	
PRIORITY INFORMATION:	FR 2003-10103 20030822
	US 2003-530233P 20031218 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Page(s)

LINE COUNT: 1427

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetic/dermatological compositions useful for preventing and/or combating the degradation of collagen fibers induced by solar radiation typically characterized by a UV-A/UV-B ratio ranging from 10 and 17, advantageously formulated for topical application onto the skin and/or scalp, contain a thus effective amount of at least one inhibitor of the production of photoinduced keratinocytic cytosoluble factors, notably sodium butyrate.

L8 ANSWER 31 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:335675 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

Stafford, Jeffrey A., San Diego, CA, UNITED STATES

Vu, Phong H., San Diego, CA, UNITED STATES

Xiao, Xiao-Yi, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004266769 A1 20041230 <--

US 7169801 B2 20070130

APPLICATION INFO.: US 2004-803344 A1 20040317 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-455437P 20030317 (60)

US 2003-531203P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE,  
SAN DIEGO, CA,

92121

NUMBER OF CLAIMS: 67

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 5381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the formula



Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 32 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:321565 USPATFULL <<LOGINID::20080212>>

TITLE: Histone deacetylase inhibitors

INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES

Brown, Jason W., San Diego, CA, UNITED STATES

Cao, Sheldon X., San Diego, CA, UNITED STATES

Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES

Stafford, Jeffrey A., San Diego, CA, UNITED STATES

Vu, Phong H., San Diego, CA, UNITED STATES

Xiao, Xiao-Yi, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004254220 A1 20041216 <--

APPLICATION INFO.: US 2004-803575 A1 20040317 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-455437P 20030317 (60)

US 2003-531203P 20031219 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: JOHN P. WOOLDRIDGE, 252 KAIPHI PL, KIHAI, HI 96753, HI,

96753

NUMBER OF CLAIMS: 95

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Page(s)

LINE COUNT: 4834

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that may be used to inhibit histone deacetylase having the formula

Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between

0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 33 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:280854 USPATFULL <<LOGINID::20080212>>

TITLE: Method of providing a steroid-sparing benefit with a  
cyclooxygenase-2 inhibitor and compositions therewith

INVENTOR(S): Seibert, Karen, St. Louis, MO, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO (U.S.  
corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004220155 A1 20041104 <--

APPLICATION INFO.: US 2004-803145 A1 20040317 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2003-458595P 20030328 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Charles E. Dunlap, P.O. Box 11070, Columbia, SC,  
29211-1070

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

LINE COUNT: 5421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is described for providing a steroid-sparing benefit to a  
subject that is in need of, or that is presently receiving, a  
corticosteroid, the method comprising administering to the subject a  
cyclooxygenase-2 inhibitor in combination with a corticosteroid.  
Therapeutic compositions, pharmaceutical compositions and kits that are  
useful for implementing the present method are also described.

L8 ANSWER 34 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:145285 USPATFULL <<LOGINID::20080212>>

TITLE: Antiangiogenic drug to treat cancer, arthritis and  
retinopathy

INVENTOR(S): Kawai, Megumi, Libertyville, IL, UNITED STATES

Henkin, Jack, Highland Park, IL, UNITED STATES

Sheppard, George S., Wilmette, IL, UNITED STATES

Craig, Richard A., Racine, WI, UNITED STATES

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004110959 A1 20040610 <--

US 6849757      B2 20050201  
APPLICATION INFO.: US 2003-616628    A1 20030710 (10)  
RELATED APPLN. INFO.: Division of Ser. No. US 1999-316856, filed on 21 May  
1999, GRANTED, Pat. No. US 6632961

NUMBER      DATE  
-----

PRIORITY INFORMATION: US 1998-86491P    19980522 (60)  
DOCUMENT TYPE:      Utility  
FILE SEGMENT:      APPLICATION  
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT  
LABORATORIES, 100 ABBOTT  
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008  
NUMBER OF CLAIMS:    17  
EXEMPLARY CLAIM:    1  
LINE COUNT:          2033  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB    Compounds having Formula I    ##STR1##

or pharmaceutically acceptable salts or prodrugs thereof, are useful for  
treating pathological states which arise from or are exacerbated by  
angiogenesis. The invention also relates to pharmaceutical compositions  
comprising these compounds and to methods of inhibiting angiogenesis in  
a mammal.

L8 ANSWER 35 OF 50 USPATFULL on STN  
ACCESSION NUMBER:    2004:145266 USPATFULL <<LOGINID::20080212>>  
TITLE:              Complementary DNAs encoding proteins with signal  
                      peptides  
INVENTOR(S):          Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE  
                      Bougueleret, Lydie, Petit Lancy, SWITZERLAND  
                      Jobert, Severin, Paris, FRANCE  
                      Clusel, Catherine, Vincennes, FRANCE  
                      Duclert, Aymeric, Saint-Maur, FRANCE  
PATENT ASSIGNEE(S):   GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

NUMBER      KIND    DATE  
-----

PATENT INFORMATION: US 2004110939    A1 20040610      <--  
                      US 2006009633    A9 20060112  
APPLICATION INFO.: US 2001-978360    A1 20011015 (9)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-663600, filed  
on 15 Sep 2000, GRANTED, Pat. No. US 6573068

NUMBER      DATE  
-----

PRIORITY INFORMATION: WO 1998-IB2122 19981217

WO 1999-IB282 19990209

WO 2000-IB951 20000621

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A  
PROFESSIONAL

ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,  
GAINESVILLE, FL, 326066669

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 7 Drawing Page(s)

LINE COUNT: 11396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The sequences of cDNAs encoding secreted proteins are disclosed. The  
cDNAs can be used to express secreted proteins or fragments thereof or  
to obtain antibodies capable of specifically binding to the secreted  
proteins. The cDNAs may also be used in diagnostic, forensic, gene  
therapy, and chromosome mapping procedures. The cDNAs may also be used  
to design expression vectors and secretion vectors.

L8 ANSWER 36 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2004:38339 USPATFULL <<LOGINID::20080212>>

TITLE: Method of making a product with a micro or nano sized  
structure and product

INVENTOR(S): Van Rijn, Cornelis Johannes Maria, Hengelo, NETHERLANDS  
Vogelaar, Laura, Enschede, NETHERLANDS  
Nijdam, Wietze, Enschede, NETHERLANDS  
Barsema, Jonathan Nathaniel, Enschede, NETHERLANDS  
Wessling, Matthias, Enschede, NETHERLANDS

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2004028875 A1 20040212 <--

APPLICATION INFO.: US 2003-433275 A1 20030929 (10)

WO 2001-NL874 20011203

NUMBER DATE

-----

PRIORITY INFORMATION: NL 2000-1016779 20001202

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: YOUNG & THOMPSON, 745 SOUTH 23RD STREET  
2ND FLOOR,

ARLINGTON, VA, 22202

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Page(s)

LINE COUNT: 2524

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Using phase separation technique perforated as well as non-perforated polymeric structures can be made with high aspect ratios (>5). By varying the phase separation process the properties (e.g. porous, non-porous, dense, open skin) of the moulded product can be tuned. Applications are described in the field of micro fluidics (e.g. micro arrays, electrophoretic boards), optics, polymeric solar cells, ball grid arrays, and tissue engineering.

L8 ANSWER 37 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:334723 USPATFULL <<LOGINID::20080212>>

TITLE: Composition containing a sapogenin and use thereof

INVENTOR(S): Besne, Isabelle, Paris, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2003235599 A1 20031225 <--

APPLICATION INFO.: US 2003-393913 A1 20030324 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: FR 2002-4611 20020412

US 2002-374157P 20020422 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940

DUKE STREET, ALEXANDRIA, VA, 22314

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM: 1

LINE COUNT: 782

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition containing a sapogenin, and/or a sapogenin ester, and to the use of a sapogenin and/or a sapogenin ester to manufacture a composition that is suitable for topical application to the skin, and in a method wherein sapogenin and/or a sapogenin ester are used as agents for the of smoothing out wrinkles and fine lines, in particular expression wrinkles and fine lines. The sapogenin may be used/provided in the form of a natural extract containing it. A preferred sapogenin is diosgenin.

L8 ANSWER 38 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:273494 USPATFULL <<LOGINID::20080212>>  
TITLE: Antiangiogenic drug to treat cancer, arthritis and  
retinopathy  
INVENTOR(S): Kawai, Megumi, Libertyville, IL, United States  
Henkin, Jack, Highland Park, IL, United States  
Sheppard, George S., Wilmette, IL, United States  
Craig, Richard A., Racine, WI, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE	
-----				
PATENT INFORMATION:	US 6632961	B1	20031014	<--
APPLICATION INFO.:	US 1999-316856		19990521 (9)	

	NUMBER	DATE
-----		
PRIORITY INFORMATION:	US 1998-86491P	19980522 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Steele, Gregory W., Donner, B. Gregory	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1933	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Compounds having Formula I ##STR1##		

or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

L8 ANSWER 39 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2003:200520 USPATFULL <<LOGINID::20080212>>  
TITLE: Intradermal-penetration agents for topical local  
anesthetic administration  
INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL  
REPUBLIC  
OF  
Huber, Petra, Muenchen, GERMANY, FEDERAL REPUBLIC OF  
Mason, Paul, Flemington, NJ, UNITED STATES  
PATENT ASSIGNEE(S): EpiCept Corp. (non-U.S. corporation)

NUMBER      KIND      DATE

-----

PATENT INFORMATION:    US 2003138505    A1   20030724      <--  
                          US 6746689      B2   20040608  
APPLICATION INFO.:    US 2002-201901    A1   20020725 (10)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-523652, filed on 10  
                          Mar 2000, GRANTED, Pat. No. US 6455066  
DOCUMENT TYPE:        Utility  
FILE SEGMENT:         APPLICATION  
LEGAL REPRESENTATIVE: PENNIE & EDMONDS LLP, 1667 K STREET NW,  
SUITE 1000,  
                          WASHINGTON, DC, 20006  
NUMBER OF CLAIMS:     39  
EXEMPLARY CLAIM:      1  
LINE COUNT:            897  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB    A non-invasive and non-systemic method for administering a local  
       anesthetic. The method comprises topical application of a local  
       anesthetic in combination with an intradermal-penetration agent selected  
       from the group consisting an aloe composition, a triglyceride, and a  
       mixture thereof.

L8 ANSWER 40 OF 50 USPATFULL on STN

ACCESSION NUMBER:     2003:141014 USPATFULL <<LOGINID::20080212>>

TITLE:                 Cell proliferation inhibitors

INVENTOR(S):          Li, Qun, Libertyville, IL, UNITED STATES  
                          Sham, Hing, Mundelein, IL, UNITED STATES  
                          Woods, Keith W., Libertyville, IL, UNITED STATES  
                          Steiner, Beth A., Remington, IN, UNITED STATES  
                          Gwaltney, Stephen L., II, Lindenhurst, IL, UNITED  
                          STATES  
                          Barr, Kenneth J., San Francisco, CA, UNITED STATES  
                          Imade, Hovis M., Chicago, IL, UNITED STATES  
                          Rosenberg, Saul, Grayslake, IL, UNITED STATES

NUMBER      KIND      DATE

-----

PATENT INFORMATION:    US 2003096856    A1   20030522      <--  
                          US 6924304      B2   20050802  
APPLICATION INFO.:    US 2002-301427    A1   20021121 (10)  
RELATED APPLN. INFO.: Division of Ser. No. US 2000-579705, filed on 26 May  
                          2000, GRANTED, Pat. No. US 6521658

NUMBER      DATE

-----

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT  
LABORATORIES, 100 ABBOTT  
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008  
NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3231  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the  
compounds, pharmaceutical compositions containing the compounds, and  
methods of treatment using the compounds are disclosed.

L8 ANSWER 41 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2003:105821 USPATFULL <<LOGINID::20080212>>  
TITLE: Cosmetic or dermatological composition comprising an  
association between an elastase inhibitor compound of  
the N-acylaminoamide family and at least one  
anti-inflammatory compound  
INVENTOR(S): Breton, Lionel, Versailles, FRANCE  
Mahe, Yann, Morsang sur Orge, FRANCE  
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003072732	A1	20030417	<--
	US 6998129	B2	20060214	
APPLICATION INFO.:	US 2002-179955	A1	20020626	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-8434	20010626
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1099	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A cosmetic or dermatological composition characterized In that it	



comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound.

L8 ANSWER 42 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:64318 USPATFULL <<LOGINID::20080212>>

TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor

INVENTOR(S): Breton, Lionel, Versailles, FRANCE  
Mahe, Yann, Morsang sur Orge, FRANCE

PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE, 75008 (non-U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2003044438 A1 20030306 <--

US 6884425 B2 20050426

APPLICATION INFO.: US 2002-179934 A1 20020626 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: FR 2001-8433 20010626

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER &  
NEUSTADT PC, FOURTH

FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA,  
22202

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

LINE COUNT: 1199

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 43 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:57103 USPATFULL <<LOGINID::20080212>>

TITLE: Anti-fungal composition

INVENTOR(S): Jira, Vic, El Monte, CA, UNITED STATES  
Jirathitikal, Vichai, Chachoengsao, THAILAND

NUMBER KIND DATE

-----

PATENT INFORMATION: US 2003039667 A1 20030227 <--

APPLICATION INFO.: US 2002-228280 A1 20020827 (10)

NUMBER DATE

-----

PRIORITY INFORMATION: US 2001-314666P 20010827 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BLANK ROME COMISKY & MCCAULEY, LLP, 900  
17TH STREET,

N.W., SUITE 1000, WASHINGTON, DC, 20006

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

LINE COUNT: 1664

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A multivalent fungal vaccine comprising one or more heat-inactivated  
fungal antigens, wherein at least one fungal antigen is effective in  
producing an immune response in a host when said vaccine is administered  
orally at a dose that is sufficient for preventing or treating the  
fungal disease in said host. Also described are methods for making and  
using an orally available anti-fungal vaccine.

L8 ANSWER 44 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:47790 USPATFULL <<LOGINID::20080212>>

TITLE: Cell proliferation inhibitors

INVENTOR(S): Li, Qun, Libertyville, IL, United States

Sham, Hing, Mundelein, IL, United States

Woods, Keith W., Libertyville, IL, United States

Steiner, Beth A., Remington, IN, United States

Gwaltney, II, Stephen L., Lindenhurst, IL, United  
States

Barr, Kenneth J., San Francisco, CA, United States

Imade, Hovis M., Chicago, IL, United States

Rosenberg, Saul, Grayslake, IL, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER KIND DATE

-----

PATENT INFORMATION: US 6521658 B1 20030218 <--

APPLICATION INFO.: US 2000-579705 20000526 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-136542, filed  
on 28 May 1999

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: McKane, Joseph K.

ASSISTANT EXAMINER: Small, Andrea D.

LEGAL REPRESENTATIVE: Donner, B. Gregory  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 2834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 45 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:246388 USPATFULL <<LOGINID::20080212>>  
TITLE: Intradermal-penetration agents for topical local  
anesthetic administration  
INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL  
REPUBLIC  
OF  
Stoeger, Katharina, Schrobenhausen, GERMANY, FEDERAL  
REPUBLIC OF  
Huber, Petra, Munich, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): Epicept Corporation, Englewood Cliffs, NJ, United  
States (U.S. corporation)

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 6455066 B1 20020924 <--  
APPLICATION INFO.: US 2000-523652 20000310 (9)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Lankford, Jr., Leon B.  
ASSISTANT EXAMINER: Coe, Susan D.  
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP  
NUMBER OF CLAIMS: 8  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 791

AB A non-invasive and non-systemic method for administering a local anesthetic. The method comprises topical application of a local anesthetic in combination with an intradermal-penetration agent selected from the group consisting an aloe composition, a triglyceride, and a mixture thereof.

L8 ANSWER 46 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:32704 USPATFULL <<LOGINID::20080212>>

TITLE: Substituted phenyl farnesyltransferase inhibitors  
INVENTOR(S): Wang, Wei-Bo, Grayslake, IL, UNITED STATES  
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES  
Fakhoury, Stephen A., Ann Arbor, MI, UNITED STATES  
Gwaltney, Stephen L., II, Lindenhurst, IL, UNITED STATES  
Hasvold, Lisa A., Grayslake, IL, UNITED STATES  
Hutchins, Charles W., Green Oaks, IL, UNITED STATES  
Li, Qun, Libertyville, IL, UNITED STATES  
Lin, Nan-Horng, Vernon Hills, IL, UNITED STATES  
Nelson, Lissa Taka Jennings, Highland Park, IL, UNITED STATES  
O'Connor, Steve, Guilford, CT, UNITED STATES  
Sham, Hing L., Vernon Hills, IL, UNITED STATES  
Sullivan, Gerard M., Round Lake Beach, IL, UNITED STATES  
Wang, Gary T., Niles, IL, UNITED STATES  
Wang, Xilu, Skokie, IL, UNITED STATES

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 2002019527 A1 20020214 <--  
APPLICATION INFO.: US 2001-842391 A1 20010425 (9)

NUMBER DATE

-----  
PRIORITY INFORMATION: US 2000-200165P 20000427 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Gregory W. Steele, Abbott Laboratories, AP6D/2 D-377,  
100 Abbott Park Road, Abbott Park, IL, 60064-6050  
NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
LINE COUNT: 9159  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds of formula (I) ##STR1##

or pharmaceutically acceptable salts thereof, inhibit  
farnesyltransferase. Methods for making the compounds, pharmaceutical  
compositions containing the compounds, and methods of treatment using  
the compounds are disclosed.

L8 ANSWER 47 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2002:5985 USPATFULL <<LOGINID::20080212>>  
TITLE: Anti-inflammatory compositions comprising peptide

derivatives of a-MSH/algal extracts  
INVENTOR(S): Mahe, Yann, Morsang sur Orge, FRANCE  
Billoni, Nelly, Valmondois, FRANCE  
Breton, Lionel, Versailles, FRANCE  
Bui-Bertrand, Lien, Savigny sur Orge, FRANCE  
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S.  
corporation)

	NUMBER	KIND	DATE	
-----				
PATENT INFORMATION:	US 6337315	B1	20020108	<--
APPLICATION INFO.:	US 1999-353650		19990715 (9)	

	NUMBER	DATE
-----		
PRIORITY INFORMATION:	FR 1998-9055	19980715
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	681	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Anti-inflammatory compositions, well suited for a wide variety of therapeutic/cosmetic applications, comprise combinatory immixture of (1) an effective anti-inflammatory amount of at least one peptide derivative of a-type melanocyte stimulating hormone (a-MSH), or functional biological equivalent thereof, and (2) an effective anti-inflammatory response-enhancing amount of at least one marine algal extract.

L8 ANSWER 48 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2001:215075 USPATFULL <<LOGINID::20080212>>  
TITLE: 3-substituted indole angiogenesis inhibitors  
INVENTOR(S): BaMaung, Nwe Y., Niles, IL, United States  
Craig, Richard A., Racine, WI, United States  
Kawai, Megumi, Libertyville, IL, United States  
Wang, Jieyi, Gurnee, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
-----			

PATENT INFORMATION: US 6323228 B1 20011127 <--  
APPLICATION INFO.: US 2000-663005 20000915 (9)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: McKane, Joseph K.  
ASSISTANT EXAMINER: D'Souza, Andrea M  
LEGAL REPRESENTATIVE: Donner, B. Gregory, Steele, Gregory  
NUMBER OF CLAIMS: 30  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1832  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB 3-Substituted indole carbohydrazides having the formula ##STR1##

are useful for inhibiting angiogenesis. Also disclosed are  
angiogenesis-inhibiting compositions and methods of inhibiting  
angiogenesis in a mammal.

L8 ANSWER 49 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 2001:67679 USPATFULL <<LOGINID::20080212>>  
TITLE: Oxazoline antiproliferative agents  
INVENTOR(S): Gwaltney, II, Stephen L., Lindenhurst, IL, United  
States  
Jae, Hwan-Soo, Glencoe, IL, United States  
Kalvin, Douglas M., Buffalo Grove, IL, United States  
Liu, Gang, Gurnee, IL, United States  
Sham, Hing L., Mundelein, IL, United States  
Li, Qun, Libertyville, IL, United States  
Claiborne, Akiyo K., Mundelein, IL, United States  
Wang, Le, Mundelein, IL, United States  
Barr, Kenneth J., San Francisco, CA, United States  
Woods, Keith W., Libertyville, IL, United States  
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

NUMBER	KIND	DATE
-----		
PATENT INFORMATION:	US 6228868	B1 20010508 <--
APPLICATION INFO.:	US 1999-360463	19990723 (9)

NUMBER	DATE
-----	
PRIORITY INFORMATION:	US 1998-94241P 19980727 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Huang, Evelyn Mei
LEGAL REPRESENTATIVE:	Steele, Gregory W., Donner, B. Gregory

NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3207  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds having Formula I ##STR1##

are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.

L8 ANSWER 50 OF 50 USPATFULL on STN  
ACCESSION NUMBER: 87:85826 USPATFULL <<LOGINID::20080212>>  
TITLE: Artificially vascularized graft  
INVENTOR(S): Viggiano, Donato A., 1090 Virginia Ave., Ft. Pierce,  
FL, United States 33450

NUMBER KIND DATE

-----  
PATENT INFORMATION: US 4713055 19871215 <--  
APPLICATION INFO.: US 1986-842351 19860318 (6)  
RELATED APPLN. INFO.: Division of Ser. No. US 1983-506858, filed on 22 Jun  
1983, now abandoned  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Rosenbaum, C. Fred  
ASSISTANT EXAMINER: Kartchner, Gene B.  
LEGAL REPRESENTATIVE: Malin, Eugene F.  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 697

AB Apparatus and method for temporarily keeping alive animal flaps or grafts by perfusing artificial blood initially through a tubular semi-permeable membrane including a plurality of capillaries and thereafter perfusing the artificial blood into the flaps or grafts.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008  
E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON

12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)  
L3 25249 S L2 AND (EMULSION?)  
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)  
L5 820 S L4 AND (CAPILLAR?)  
L6 70 S L5 AND (SKIN(P)CAPILLAR?)  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 50 S L7 AND (PY<=2005)

=> fil stnguide

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		130.87	193.34

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 8, 2008 (20080208/UP).

=> fil caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.48	193.82

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2008 VOL 148 ISS 7  
FILE LAST UPDATED: 11 Feb 2008 (20080211/ED)



Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008

E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON

12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)

L3 25249 S L2 AND (EMULSION?)

L4 3019 S L3 AND (NERV? OR ENDOCRIN?)

L5 820 S L4 AND (CAPILLAR?)

L6 70 S L5 AND (SKIN(P)CAPILLAR?)

L7 70 DUP REM L6 (0 DUPLICATES REMOVED)

L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

=> s l8 and perfluoro?

56097 PERFLUORO?

L9 0 L8 AND PERFLUORO?

=> s perfluor?

L10 59156 PERFLUOR?

=> s l10 and emulsion?

255416 EMULSION?

L11 3000 L10 AND EMULSION?

=> s l11 and (skin? or epiderm?)

285149 SKIN?

88566 EPIDERM?

L12 125 L11 AND (SKIN? OR EPIDERM?)

=> s l12 and (capilar?)

19 CAPILAR?  
L13 0 L12 AND (CAPILAR?)

=> s 112 and blood?  
1367344 BLOOD?  
L14 14 L12 AND BLOOD?

=> dup rem 14  
ENTER L# LIST OR (END):114  
'14' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS'  
You have entered a file name of duplicates to keep that is not  
referenced by any of the L#s specified for this DUPLICATE command.  
The file names of duplicates that can be kept are listed above.  
Please enter one of these file names.

=> dup rem 114  
PROCESSING COMPLETED FOR L14  
L15 14 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib ab 1-  
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L15 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:999474 CAPLUS <<LOGINID::20080212>>  
DOCUMENT NUMBER: 147:330635  
TITLE: Cell labeling with perfluorocarbon nanoparticles for  
magnetic resonance imaging and spectroscopy  
INVENTOR(S): Wickline, Samuel A.; Lanza, Gregory M.  
PATENT ASSIGNEE(S): Washington University, USA  
SOURCE: PCT Int. Appl., 84pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007100715	A2	20070907	WO 2007-US4823	20070223
WO 2007100715	A3	20080110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,  
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,  
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-776743P P 20060224

AB Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled cells under clin. relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic resonance imaging and spectroscopy data from two distinct sets of cells labeled with distinct types of perfluorocarbon nanoparticles.

L15 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1271365 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 147:508703

TITLE: Methods for assessing cell labeling

INVENTOR(S): Ahrens, Eric T.; Kornblith, Paul

PATENT ASSIGNEE(S): Celsense Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007258886	A1	20071108	US 2007-787520	20070416

PRIORITY APPLN. INFO.: US 2006-792242P P 20060414

AB The disclosure relates to methods for labeling cells ex vivo with imaging agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked in vivo by MRI, PET or other techniques. In part, the disclosed methods involve labeling a series of cell samples ex vivo determining the association of label with the cells, such that an appropriate dosage of labeled cells can be determined for each patient. Thus, a linear perfluoropolyether (PFPE) mol. was conjugated to com. available dyes, such as Bodipy-TR dye and Alexa 647. Emulsions were made using blended mixts. of the PFPE-dye conjugate and the nonconjugated PFPE. It is expected that the materials would show a small particle size of comparable size as the nonfluorescent versions, the fluorescent properties would be

maintained, the materials would show a dose dependent fluorescence intensity, the fluorescent spectrum would be unaffected by the conjugation to the PFPE, and labeled cells would exhibit similar cell loading characteristics as the nonfluorescent equivalent It is also expected that cells labeled with the dual mode agent would show a linear correlation with <sup>19</sup>F NMR-measured uptake.

L15 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:498341 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 143:13425

TITLE: Preparation for treating neurogenic and endocrine disorders of microcirculation

INVENTOR(S): Klyushnik, T. P.; Lushnikov, K. V.; Chemeris, N. K.;  
Tikhonova, I. V.; Tankanag, A. V.; Shibaev, N. V.;  
Korneeva, R. V.

PATENT ASSIGNEE(S): Otkrytoe Aktsionernoe Obshchestvo "Faberlik", Russia

SOURCE: Russ., No pp. given

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
RU 2253440	C1	20050610	RU 2004-109556	20040331
WO 2005094778	A1	20051013	WO 2005-RU132	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1744726	A1	20070124	EP 2005-731686	20050323
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007275097	A1	20071129	US 2007-594171	20070718
PRIORITY APPLN. INFO.: RU 2004-109556 A 20040331				
WO 2005-RU132 W 20050323				

AB The present innovation deals with applying prepns. affecting the values of blood microcirculation in skin. The suggested preparation is the

emulsion of perfluorocarbons that increases skin resistance to neg.  
impacts and favorably affects microcirculation by steadily increasing its  
total level that enables to improve the state of microcirculatory canal of  
skin.

L15 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:270036 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 140:281418

TITLE: Control of nitric oxide bioactivity by  
perfluorocarbons, and therapeutic use

INVENTOR(S): Nudler, Evgeny; Rafikova, Ruslan; Rafikova, Olga

PATENT ASSIGNEE(S): New York University, USA

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026345	A1	20040401	WO 2003-US29067	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003270689	A1	20040408	AU 2003-270689	20030917
US 2004127425	A1	20040701	US 2003-663693	20030917
PRIORITY APPLN. INFO.: US 2002-411828P P 20020919 WO 2003-US29067 W 20030917				

AB Perfluorocarbons are used to control nitric oxide metabolism, either to  
inhibit nitric oxide activity or to potentiate the effects of nitric  
oxide. Perfluorocarbons can be used e.g. to treat hypotension and  
vasoplegia in septic shock, to protect against myocardial  
ischemia-reperfusion injury, to treat hypertension, and to provide  
antiplatelet effects.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:162309 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 140:205217

TITLE: System for exsanguinous metabolic support of an organ  
or tissue

INVENTOR(S): Brasile, Lauren

PATENT ASSIGNEE(S): Breonics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S.  
Ser. No. 849,618.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2004038192	A1	20040226	US 2003-443452	20030522
---------------	----	----------	----------------	----------

US 6642045	B1	20031104	US 2000-547843	20000412
------------	----	----------	----------------	----------

US 2002012988	A1	20020131	US 2001-849618	20010504
---------------	----	----------	----------------	----------

US 6582953	B2	20030624		
------------	----	----------	--	--

WO 2004105484	A1	20041209	WO 2004-US16085	20040521
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-129257P P 19990414

US 2000-547843 A2 20000412

US 2001-849618 A2 20010504

WO 2000-US9894 W 20000413

US 2003-443452 A 20030522

AB An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed that employs a warm perfusion solution capable of altering the production of nitric oxide (NO) in an organ or tissue and supporting the metabolism of the organ or tissue at normothermic temps. Perfusion with the solution of the invention can therefore be used to regulate nitric oxide production in situations where it is desirable to do so, e.g. to prevent reperfusion injury. The system also monitors parameters of the circulating perfusion solution, such as pH,

temperature, osmolality, flow rate, vascular pressure and partial pressure of respiratory gases, and nitric oxide (NO) concentration and regulates them to insure that the organ is maintained under near-physiol. conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, to treat cardiovascular disorders, to prevent reperfusion injury, as a pharmaceutical delivery system and prognosticator of post-transplantation organ function is also disclosed.

L15 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:850188 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 135:111790

TITLE: Compatibility of different colloid plasma expanders  
with perflubron emulsion: an intravital microscopic  
study in the hamster

AUTHOR(S): Nolte, Dirk; Pickelmann, Sven; Lang, Michael; Keipert,  
Peter; Messmer, Konrad

CORPORATE SOURCE: Department of Oral and Maxillofacial Surgery-Regional  
Plastic Surgery, Ruhr-University of Bochum, Bochum,  
Germany

SOURCE: Anesthesiology (2000), 93(5), 1261-1270

CODEN: ANESAV; ISSN: 0003-3022

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Perfluorocarbon-based oxygen carriers have been proposed as an adjunct to autologous blood conservation techniques during elective surgery. To date, the effects of perfluorocarbon emulsions at the microcirculatory level have not been studied extensively. In this study the effects of perflubron emulsion on the microcirculation after acute normovolemic hemodilution (ANH) were investigated using different colloid plasma expanders. The dorsal skin fold chamber model and intravital fluorescence microscopy were used for anal. of the microcirculation in the thin striated skin muscle of conscious hamsters (body weight, 40-60 g). Measurements of microvascular perfusion and leukocyte adhesion (n = 6 animals per exptl. group) were made before and at 10, 30, and 60 min after ANH (to hematocrit 0.3) with either 6% hydroxyethyl starch 200/0.6 (HES), 3.5% gelatin, 5% human serum albumin (HSA), or 6% dextran 60 (DX-60) followed by i.v. injection of 3 mL/kg body weight of a 60% weight/volume perfluorocarbon emulsion based on perflubron (perfluorooctyl bromide) emulsified with egg yolk lecithin. Acute normovolemic hemodilution with HES, gelatin, or HSA followed by injection of perflubron emulsion elicited no alterations of local microvascular perfusion or leukocyte-endothelium interaction as assessed in arterioles and postcapillary venules. However, ANH with DX-60 followed by injection of perflubron emulsion led to a significant reduction of erythrocyte velocity

in postcapillary venules and an increase in venular leukocyte sticking that was never observed with DX-60 alone. Conclusions: Hydroxyethyl starch, gelatin, and HSA are compatible with perflubron emulsion in the setting of ANH. Only DX-60 appeared to be incompatible with perflubron emulsion, as evidenced by impairment of capillary perfusion.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:727886 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 134:247049

TITLE: Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers

AUTHOR(S): Noveck, Robert J.; Shannon, E. J.; Leese, Phillip T.; Shorr, Jolene S.; Flaim, Kathryn E.; Keipert, Peter E.; Woods, Catherine M.

CORPORATE SOURCE: Clinical Research Center, New Orleans, LA, USA

SOURCE: Anesthesia & Analgesia (Baltimore) (2000), 91(4), 812-822

CODEN: AACRAT; ISSN: 0003-2999

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To test the safety of a 2nd-generation perflubron-based emulsion (60% perfluorocarbon [PFC] wt/vol; Oxygent) with a small mean particle size, two parallel, randomized, double-blinded, placebo-controlled studies were conducted in healthy volunteers. The study focused on safety concerning immune function. The subjects received either perflubron emulsion i.v. (1.2 or 1.8 g PFC/kg) or saline. Perflubron emulsion had no effect on delayed hypersensitivity skin reactions, lymphocyte proliferative potential, circulating Igs, complement activation, or plasma concns. of inflammatory cytokines. The emulsion was generally well tolerated, although there was a dose-dependent increase in minor flu-like symptoms 24 h after perflubron administration. The clin. safety profile of perflubron emulsion supports its continued investigation as a temporary O carrier in surgical patients to reduce exposure to allogeneic blood transfusion.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:12216 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 130:71307

TITLE: Cosmetic skin or hair care compositions containing



perfluorocarbons infused with carbon dioxide  
 INVENTOR(S): Penska, Christine; Santhanam, Uma; Habif, Stephan  
 PATENT ASSIGNEE(S): Chesebrough-Pond's USA Co., USA  
 SOURCE: U.S., 7 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5851544	A	19981222	US 1997-993294	19971218
JP 11228382	A	19990824	JP 1998-342956	19981202
EP 938890	A2	19990901	EP 1998-309869	19981202
EP 938890	A3	20010704		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 190943	A1	20030906	IN 1998-BO781	19981202
CA 2255108	A1	19990618	CA 1998-2255108	19981203
ZA 9811274	A	20000609	ZA 1998-11274	19981209
MX 9810717	A	20020312	MX 1998-10717	19981215
CN 1231173	A	19991013	CN 1998-126971	19981218
PRIORITY APPLN. INFO.: US 1997-993294 A 19971218				
AB Cosmetic skin or hair care compns. containing a liquid, inert, hydrophobic fluorocarbon infused with carbon dioxide. The compns. increase blood flow to the skin, thus increasing endogenous oxygen and nutrient delivery to the skin. An oil-in-water cream contained perfluorodecalin infused with carbon dioxide 0.15, mineral oil 4, Brij-56 4, Alfol-16RD 4, triethanolamine 0.75, butane-1,3-diol 3, xanthan gum 0.3, perfume qs, BHT 0.01 and water to 100% by weight				
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L15 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1998:803934 CAPLUS <<LOGINID::20080212>>  
 DOCUMENT NUMBER: 130:33019  
 TITLE: Anti-inflammatory agents for prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions  
 INVENTOR(S): Long, David M., Jr.  
 PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA  
 SOURCE: U.S., 17 pp., Cont.-in-part of U.S. 5,284,645.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 7  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847009	A	19981208	US 1993-138485	19931015
US 4865836	A	19890912	US 1986-818690	19860114
US 4987154	A	19910122	US 1987-82846	19870805
AU 8939649	A	19910117	AU 1989-39649	19890705
US 5284645	A	19940208	US 1989-417796	19891004
US 5393513	A	19950228	US 1993-100664	19930730
WO 9510306	A1	19950420	WO 1994-US11590	19941014
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9480161	A	19950504	AU 1994-80161	19941014
US 6361792	B1	20020326	US 1998-206805	19981207
PRIORITY APPLN. INFO.:			US 1986-818690	A2 19860114
			US 1987-82846	A2 19870805
			US 1989-417796	A2 19891004
			WO 1989-US2948	A 19890705
			US 1989-387947	A1 19890824
			US 1991-811026	B1 19911219
			US 1993-138485	A 19931015
			WO 1994-US11590	W 19941014

AB Methods are provided for preventing or ameliorating the transient adverse  
physiol. response to particulate dispersions (TAPR response) when these  
dispersions are administered parenterally to a patient. The methods  
comprise the administration of a prophylactic anti-inflammatory drug prior  
to administration of the particulate-containing material, and optionally  
during administration as well. Preferred drugs are cyclooxygenase  
inhibitors and corticosteroids.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES  
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:750094 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 126:26599

TITLE: Increased antioxidant capacity, suppression of free  
radical damage and erythrocyte aggregation after  
combined application of alpha-tocopherol and FC-43  
perfluorocarbon emulsion in early postburn period  
in rats

AUTHOR(S): Bekyarova, G.; Yankova, T.; Galunska, B.

CORPORATE SOURCE: Department Pathophysiology, University Medicine Varna,

Varna, 9002, Bulg.  
SOURCE: Artificial Cells, Blood Substitutes, and  
Immobilization Biotechnology (1996), 24(6), 629-641  
CODEN: ABSBE4; ISSN: 1073-1199

PUBLISHER: Dekker  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The aim of the present study was to examine the antioxidant capacity, free radical-mediated damage, and erythrocyte aggregation in plasma of rats with thermal skin injury in the early postburn period and to evaluate the effect of treatment with  $\alpha$ -tocopherol and FC-43 perfluorocarbon emulsion alone and in combination. Thermal skin injury in rats reduced the antioxidant capacity, enhanced free radical-mediated damage, and erythrocyte aggregation on the 3rd hour after injury. The combined application of  $\alpha$ -tocopherol and FC-43 immediately after thermal skin injury in rats increased the plasma antioxidant capacity, decreased free radical-mediated damage of erythrocytes, and suppressed their aggregation on the 3rd hour after the injury.

L15 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:849295 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 123:237830

TITLE: Fluorocarbon-containing oil emulsions as oxygen  
carriers

INVENTOR(S): von Werner, Konrad; Gross, Udo

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Ger. Offen., 7 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4405627	A1	19950824	DE 1994-4405627	19940222
EP 670159	A1	19950906	EP 1995-102244	19950218

R: CH, DE, FR, GB, IT, LI, NL

PRIORITY APPLN. INFO.: DE 1994-4405627 A 19940222

OTHER SOURCE(S): MARPAT 123:237830

AB Aqueous emulsions of oils addnl. containing a fluorocarbon (RF)xARH [RF = highly

fluorinated alkyl; RH = H, alkyl; A = O, S, (OCH<sub>2</sub>CH<sub>2</sub>)<sub>p</sub>; x = 1-4; p = 1, 2]  
or an oligomer of the type [Y(CF<sub>2</sub>)<sub>a</sub>Ob(CH<sub>2</sub>)<sub>c</sub>CH:CH<sub>2</sub>]<sub>n</sub> (Y = H, F; a = 2-16;  
b, c = 0, 1; n = 2-4) are useful for O transport in the vascular system,

the dermis, biotechnol., fermentation, and cell culture, as well as for vehicles for drugs and contrast agents and as stds. in blood gas monitoring.  
Thus, a mixture of 1H-perfluorooctane 30, soybean oil 3.5, and 9% aqueous phospholipid solution to 50 mL was sonicated to a mean particle size of 110 nm and autoclaved at 121- for i.v. administration as an O-transporting medium.

L15 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:465307 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 121:65307

TITLE: Amphiphilic sulfurated, fluorinated and polyglycerol  
surfactant compounds, cosmetic or pharmaceutical  
composition containing them, preparation process and  
vesicles formed

INVENTOR(S): Bollens, Eric; Mahieu, Claude

PATENT ASSIGNEE(S): Fr.

SOURCE: Can. Pat. Appl., 53 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2101620	A1	19940130	CA 1993-2101620	19930729
FR 2694289	A1	19940204	FR 1992-9404	19920729
FR 2694289	B1	19941014		
US 5459165	A	19951017	US 1993-99488	19930727
EP 585157	A1	19940302	EP 1993-401976	19930729
EP 585157	B1	19960320		
R: AT, BE, CH, DE, DK, ES, GB, GR, IE, IT, LI, NL, PT, SE				
JP 06192217	A	19940712	JP 1993-188335	19930729
AT 135686	T	19960415	AT 1993-401976	19930729
ES 2085739	T3	19960601	ES 1993-401976	19930729
US 5591449	A	19970107	US 1995-502463	19950414
PRIORITY APPLN. INFO.:			FR 1992-9404	A 19920729
			US 1993-99488	A3 19930727

OTHER SOURCE(S): MARPAT 121:65307

AB The title agents  $R_f(CH_2)_mSGnH$  [ $R_f$  = perfluorinated C6-20 alkyl radical;  
m = 0, 1, 2; n = 2-10; G =  $CH_2CH(CH_2OH)O$ ,  $CH(CH_2OH)CH_2O$ ,  
 $CH_2CH(O)CH_2O$ ,

etc.] are useful as surfactants in cosmetic or pharmaceutical compns.

Some of the compds. are nonionic amphiphilic lipids capable of forming lamellar vesicles. 1-(F-hexyl)-5,9,10-ol-7-oxa-3-thiodecane (I) was prepared from 2-F-hexylethanethiol and glycidyl ether and

isopropylideneglyceryl. I was used in an antiaging serum.

L15 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:692319 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 121:292319

TITLE: Characterization and mechanism of side-effects of  
Oxygent HT (highly concentrated fluorocarbon  
emulsion) in swine

AUTHOR(S): Flaim, S.F.; Hazard, D.R.; Hogan, J.; Peters, R.M.

CORPORATE SOURCE: Alliance Pharmaceutical Corp., San Diego, CA, 92121,  
USA

SOURCE: Artificial Cells, Blood Substitutes, and  
Immobilization Biotechnology (1994), 22(4), 1511-15  
CODEN: ABSBE4; ISSN: 1073-1199

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Perfluorooctyl bromide is an oxygen-carrying perfluorocarbon presently under development as an artificial blood substitute (Oxygent<sup>TM</sup> HT). Oxygent HT i.v. elicits a mild side-effect profile in man characterized by early onset headache and nausea and delayed onset fever. Early onset flushing has also been observed. Species of Artiodactyla are sensitive to particulate injections and demonstrate a transient pulmonary hypertensive response thought to be associated with the large number of pulmonary intravascular macrophages found in these species. Because of this sensitivity, we chose the swine as a model for further investigations. In anesthetized and conscious swine, i.v. Oxygent HT transiently increased mean pulmonary artery pressure (mPAP) and caused flushing. Both effects peaked at 30 min post injection and were resolved by 2 h. Plasma thromboxane B<sub>2</sub> (TxB) increased in response to Oxygent HT. Oxygent HT-induced changes in mPAP, flush, and plasma TxB were blocked by aspirin and ibuprofen. Dexamethasone and SQ 29,548 (thromboxane receptor antagonist) blocked the mPAP increase. In conscious swine, Oxygent HT caused a febrile response which was blocked by ibuprofen or dexamethasone. Thus, both early- and late-onset effects of Oxygent HT in swine are blocked by interference with the arachidonic acid cascade. These findings suggest that the 2-phase "flu-like" syndrome induced by Oxygent HT is secondary to the release of products of the arachidonic acid cascade and may be effectively prophylaxed in man with corticosteroids or long plasma half-life cyclooxygenase inhibitors.

L15 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:579293 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 93:179293

ORIGINAL REFERENCE NO.: 93:28399a,28402a

TITLE: A new look at the vapor pressure problem in red cell  
substitutes

AUTHOR(S): Clark, Leland C., Jr.; Moore, Robert E.; Diver, Sunny;  
Miller, Marian L.  
CORPORATE SOURCE: Children's Hosp. Res. Found., Cincinnati, OH, 45229,  
USA  
SOURCE: International Congress Series (1979), 486(Proc. Int.  
Symp. Perfluorochem. Blood Substitutes, 4th, 1978),  
55-67  
CODEN: EXMDA4; ISSN: 0531-5131  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB About 30 fluorocarbons, most of them newly-synthesized cyclic  
perfluorocarbons, such as alkyl-substituted cyclohexanes, were injected  
i.p. at a dose of 5 mL/kg in mice. Such compds. were found to be  
transpired at rates from a few to hundreds of nanograms per min. In  
compds. having the same vapor pressure and mol. weight and containing only C and  
F great differences in rates of elimination are found. I.p. emulsions  
were transpired at nearly the same rate as i.v. emulsions. This method  
makes it possible to evaluate new structures quant. for their rate of  
transpiration. In addition, the exodus rates of mixts. of known compds. and  
isomers were measured by this method. Each cyclic and aliphatic fluorocarbon  
has a characteristic rate at which the vapors from the peritoneal cavity  
leave. Both chemical structure and vapor tension must be considered when  
designing fluorocarbon red cell substitutes which must leave the body by  
transpiration.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008  
E PERFLUOROCARBON

L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT  
13:14:28 ON  
12 FEB 2008

L2 143119 S L1 OR (PERFLUOR?)  
L3 25249 S L2 AND (EMULSION?)  
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)  
L5 820 S L4 AND (CAPILLAR?)  
L6 70 S L5 AND (SKIN(P)CAPILLAR?)  
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)  
L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

L9        0 S L8 AND PERFLUORO?  
L10      59156 S PERFLUOR?  
L11      3000 S L10 AND EMULSION?  
L12      125 S L11 AND (SKIN? OR EPIDERM?)  
L13      0 S L12 AND (CAPILAR?)  
L14      14 S L12 AND BLOOD?  
L15      14 DUP REM L14 (0 DUPLICATES REMOVED)